KIM-1 Shows Prognostic and Predictive Value With Adjuvant Atezolizumab in RCC
Lenvatinib/Pembrolizumab Yields Greater Clinical Benefit vs Sunitinib Regardless of Biomarker Subtypes in ccRCC
CRS, ICANS Incidence Reduced to Zero Following Tocilizumab, Teclistamab Administration in R/R Multiple Myeloma
Belantamab Mafodotin Plus BVd Produces PROs Comparable to DVd in Relapsed/Refractory Multiple Myeloma